Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency.

[1]  H. Uchi,et al.  A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma. , 2019, Current oncology.

[2]  M. Kanai,et al.  Genetic and phenotypic landscape of the major histocompatibilty complex region in the Japanese population , 2019, Nature Genetics.

[3]  K. Ohe,et al.  A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma , 2019, The American journal of case reports.

[4]  F. Hodi,et al.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. , 2018, Endocrine reviews.

[5]  T. Pawlik,et al.  Histopathological and immunophenotypic features of ipilimumab‐associated colitis compared to ulcerative colitis , 2018, Journal of internal medicine.

[6]  A. Pontecorvi,et al.  Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients , 2018, Clinical endocrinology.

[7]  Peng-fei Wang,et al.  Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis , 2017, Front. Pharmacol..

[8]  W. Barry,et al.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[9]  F. Hodi,et al.  Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.

[10]  H. Gogas,et al.  Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy , 2017, Cancer investigation.

[11]  Andreas Handel,et al.  Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells , 2017, Nature.

[12]  K. Ohnaka,et al.  Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab , 2017, Japanese journal of clinical oncology.

[13]  M. Cosottini,et al.  Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. , 2016, The American journal of pathology.

[14]  A. Sugawara,et al.  Diagnosis and treatment of adrenal insufficiency including adrenal crisis: a Japan Endocrine Society clinical practice guideline [Opinion]. , 2016, Endocrine journal.

[15]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[16]  L. Liau,et al.  HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. , 2015, The Journal of clinical endocrinology and metabolism.

[17]  D. Middleton,et al.  Determination of HLA‐A, ‐C, ‐B, ‐DRB1 allele and haplotype frequency in Japanese population based on family study , 2015, Tissue antigens.

[18]  G. Chrousos,et al.  Adrenal insufficiency , 2014, The Lancet.

[19]  J. Wolchok,et al.  Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody , 2014, Science Translational Medicine.

[20]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[21]  O. Karadag,et al.  Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey , 2012, Arthritis Research & Therapy.

[22]  C. Punt,et al.  PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer , 2012, Journal of immunotherapy.

[23]  Simon C. Potter,et al.  Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.

[24]  A. Imagawa,et al.  Class II HLA genotype in fulminant type 1 diabetes: A nationwide survey with reference to glutamic acid decarboxylase antibodies , 2011, Journal of diabetes investigation.

[25]  D. Goodman,et al.  Anti-GBM disease following CTLA4 blockade in a patient with metastatic melanoma , 2010 .

[26]  S. Holdsworth,et al.  IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. , 2009, Journal of the American Society of Nephrology : JASN.

[27]  T. Hibi,et al.  IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease , 2008, Gut.

[28]  F. Mihara,et al.  Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. , 2005, Brain : a journal of neurology.

[29]  A. Rees,et al.  The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. , 1999, Kidney international.

[30]  S. Makino,et al.  Lymphocytic adenohypophysitis and lymphocytic infundibuloneurohypophysitis. , 1997, Endocrine journal.

[31]  H. Inoko,et al.  Analysis of genes within the HLA region affecting susceptibility to ulcerative colitis. , 1993, Human immunology.

[32]  J. Säfwenberg,et al.  Influence of the HLA-DR4 antigen and iodine status on the development of autoimmune postpartum thyroiditis. , 1985, The Journal of clinical endocrinology and metabolism.

[33]  R. Jansson,et al.  INFLUENCE OF HLA-DR4 ON THE DEVELOPMENT OF AUTOIMMUNE POSTPARTUM THYROIDITIS1 , 1985 .